Plain-English translation of NCT02519322 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial examined whether —an immune-boosting medication—given alone or combined with other immune drugs before surgery could help shrink advanced melanoma tumors in patients with stage III or oligometastatic stage IV disease. After surgery, participants continued receiving the medication to help prevent the cancer from coming back. The trial studied how well these treatments worked and how safe they were.
Advanced melanoma is difficult to treat and often comes back after surgery. This trial was designed to see whether giving immune-boosting medications before surgery could help the body's own immune system fight the cancer more effectively, shrink tumors, and reduce the risk of recurrence.
Participants received immune-boosting medications by intravenous infusion over several weeks before undergoing surgery to remove their melanoma tumors on day 57. After surgery, they continued receiving the same medication every 2 to 4 weeks for several months. Throughout the study, participants underwent blood tests, imaging scans, and tumor biopsies to assess how well the treatment was working and to monitor for side effects.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States